<DOC>
	<DOCNO>NCT01411267</DOCNO>
	<brief_summary>This phase I study investigational drug AC220 combine cytarabine etoposide patient relapse acute lymphoblastic leukemia ( ALL ) acute myelogenous leukemia ( AML ) .</brief_summary>
	<brief_title>A Phase I Study AC220 Children With Relapsed Refractory Acute Lymphoblastic Leukemia Acute Myelogenous Leukemia</brief_title>
	<detailed_description>This study patient relapse acute lymphoblastic leukemia ( ALL ) acute myelogenous leukemia ( AML ) . Some people diagnose leukemia change receptor located surface white blood cell call FLT3 . This known FLT3 mutation . FLT3 play important role way cell grow divide . In normal cell , FLT3 receptor switch time switch get chemical signal outside . But cell FLT3 mutation grow signal permanently switch . This mean leukemia cell FLT3 mutation grow dividing time . Doctors find people leukemia cell carry FLT3 mutation less likely go remission chemotherapy high risk leukemia come back treatment . This study investigational drug call AC220 . AC220 consider investigational approve United States Food Drug Administration ( FDA ) . AC220 drug able `` turn '' FLT3 grow signal . AC220 give cytarabine etoposide treat relapse leukemia . This phase I study , mean study do find high dose AC220 give safely drug cytarabine etoposide child young adult .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Acute Disease</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>Patients must great 1 month ≤ 21 year age study entry . Patients must diagnosis relapsed/refractory AML , ALL acute leukemia ambiguous lineage meet follow criterion : 1 . Patients AML leukemia ambiguous lineage must great equal 5 % blast bone marrow . 2 . Patients ALL must M3 marrow ( marrow blast &gt; 25 % ) . 3 . Patients ALL must MLL gene rearrangement hyperdiploid &gt; 50 chromosome . 4 . Patients treatment relate AML ( tAML ) eligible , provide meet eligibility criterion . Karnofsky &gt; 50 % patient &gt; 16 year age Lansky &gt; 50 % patient ≤16 year age . Patients must fully recover acute toxic effect prior chemotherapy , immunotherapy , radiotherapy prior enter study . Myelosuppressive chemotherapy : Patients ALL relapse standard maintenance therapy eligible time relapse . For patient ALL AML relapse receive cytotoxic therapy , least 14 day must elapse since completion cytotoxic therapy . Cytoreduction hydroxyurea initiate continue 24 hour prior start AC220 . Patients receive FLT3 inhibitor ( ex . lestaurtinib , sorafenib ) eligible study . Hematopoietic growth factor : At least 7 day since completion therapy growth factor . Biologic ( antineoplastic agent ) : At least 7 day since completion therapy biologic agent . For agent know adverse event occur beyond 7 day administration , period must extend beyond time adverse event know occur . The duration interval must discuss study chair . XRT : 2 wks must elapse since local palliative XRT CNS chloromas ; No washout period necessary chloromas ; least 3 month must elapse prior TBI , craniospinal XRT . Hematopoetic Stem Cell Transplant : At least 90 day must elapse since hematopoietic stem cell transplant ( HSCT ) patient must active GVHD . Patient must adequate renal hepatic function indicate follow laboratory value : Patients must calculate creatinine clearance radioisotope GFR ≥70mL/min/1.73m2 normal serum creatinine base age/gender . Total bilirubin &lt; 1.5 x ULN age normal conjugate bilirubin . Alanine transaminase ( ALT ) &lt; 5 × ULN ( unless relate leukemic involvement ) . Patient must shorten fraction ≥ 27 % echocardiogram , OR ejection fraction ≥ 50 % radionuclide angiogram . Reproductive Function Female patient childbearing potential must negative urine serum pregnancy test confirm within 2 week prior enrollment . Female patient infant must agree breastfeed infant study . Male female patient childbearing potential must agree use effective method contraception approve investigator study minimum 6 month study treatment . Patients exclude CNS 3 disease . Patients exclude uncontrolled significant cardiovascular disease , include : A myocardial infarction within 12 month . Uncontrolled angina within 6 month . Diagnosed suspected congenital long QT syndrome history clinically significant ventricular arrhythmia ( ventricular tachycardia , ventricular fibrillation , torsades de pointes [ TdP ] ) ; history arrhythmia discuss Sponsor 's Medical Monitor prior patient 's entry study . Prolonged QTcF interval preentry ECG ( ≥450 m ) . Any history second third degree heart block ( may eligible patient currently pacemaker ) . Heart rate &lt; 50/minute preentry ECG . Uncontrolled hypertension . Complete leave bundle branch block . Any history clinically significant ventricular arrhythmia ( ventricular tachycardia , ventricular fibrillation , TdP . Patients exclude systemic fungal , bacterial , viral infection exhibit ongoing signs/symptoms related infection without improvement despite appropriate antibiotic treatment . The patient need pressor negative blood culture 48 hour . Patient receive plan receive concomitant chemotherapy , radiation therapy , immunotherapy specify protocol . Any significant concurrent disease , illness , psychiatric disorder social issue would compromise patient safety compliance , interfere consent , study participation , follow , interpretation study result . Patients concurrently receive CYP3A4 5 inhibitor inducer</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Relapse</keyword>
	<keyword>Lymphoblastic</keyword>
	<keyword>Leukemia</keyword>
	<keyword>AC220</keyword>
	<keyword>Refractory</keyword>
	<keyword>Myelogenous</keyword>
	<keyword>Acute</keyword>
	<keyword>Childhood</keyword>
	<keyword>Pediatric</keyword>
	<keyword>ALL</keyword>
	<keyword>AML</keyword>
</DOC>